Maxim Group Starts Cellular Biomedicine Group (CBMG) at Buy

September 21, 2016 5:28 PM EDT Send to a Friend
Maxim Group initiates coverage on Cellular Biomedicine Group (NASDAQ: CBMG) with a Buy rating and a price target of $16.00.Analyst ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login